menu
    • menu
    [{"orgOrder":0,"company":"GenScript Biotech Corporation","sponsor":"Beroni Group","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2020","type":"Collaboration","leadProduct":"Nanobodies","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"GenScript Biotech Corporation","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"GenScript Biotech Corporation \/ Beroni Group","highestDevelopmentStatusID":"4","companyTruncated":"GenScript Biotech Corporation \/ Beroni Group"},{"orgOrder":0,"company":"GenScript Biotech Corporation","sponsor":"Xiangxue Life Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"TAEST16001","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"GenScript Biotech Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GenScript Biotech Corporation \/ GenScript","highestDevelopmentStatusID":"6","companyTruncated":"GenScript Biotech Corporation \/ GenScript"},{"orgOrder":0,"company":"GenScript Biotech Corporation","sponsor":"REMD","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Collaboration","leadProduct":"Bispecific Antibody","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"GenScript Biotech Corporation","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"GenScript Biotech Corporation \/ REMD","highestDevelopmentStatusID":"3","companyTruncated":"GenScript Biotech Corporation \/ REMD"},{"orgOrder":0,"company":"GenScript ProBio","sponsor":"Initium Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Large molecule","year":"2020","type":"Collaboration","leadProduct":"Antibody-based therapeutics","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Discovery Platform","graph3":"GenScript ProBio","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"","sponsorNew":"GenScript ProBio \/ Initium Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"GenScript ProBio \/ Initium Therapeutics"},{"orgOrder":0,"company":"GenScript Biotech Corporation","sponsor":"InnoBation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Agreement","leadProduct":"IBC 101","moa":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"GenScript Biotech Corporation","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"GenScript Biotech Corporation \/ InnoBation","highestDevelopmentStatusID":"1","companyTruncated":"GenScript Biotech Corporation \/ InnoBation"},{"orgOrder":0,"company":"GenScript ProBio","sponsor":"Neoletix","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Large molecule","year":"2021","type":"Collaboration","leadProduct":"Recombinant Human Coagulation Factor VIII","moa":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"GenScript ProBio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"GenScript ProBio \/ Neoletix","highestDevelopmentStatusID":"4","companyTruncated":"GenScript ProBio \/ Neoletix"},{"orgOrder":0,"company":"GenScript ProBio","sponsor":"Synimmune","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Collaboration","leadProduct":"Flysyn","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GenScript ProBio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GenScript ProBio \/ Synimmune","highestDevelopmentStatusID":"7","companyTruncated":"GenScript ProBio \/ Synimmune"},{"orgOrder":0,"company":"GenScript ProBio","sponsor":"AskGene Pharma Inc.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Single-domain Antibody","moa":"Checkpoint","graph1":"Oncology","graph2":"Discovery","graph3":"GenScript ProBio","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"GenScript ProBio \/ AskGene","highestDevelopmentStatusID":"2","companyTruncated":"GenScript ProBio \/ AskGene"},{"orgOrder":0,"company":"GenScript ProBio","sponsor":"GenScript ProBio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Cell and Gene therapy","year":"2022","type":"Partnership","leadProduct":"Genetically Modified Mesenchymal Stem Cells Therapy","moa":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"GenScript ProBio","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"GenScript ProBio \/ GenScript ProBio","highestDevelopmentStatusID":"1","companyTruncated":"GenScript ProBio \/ GenScript ProBio"},{"orgOrder":0,"company":"GenScript ProBio","sponsor":"DAAN Bio Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"GenScript ProBio","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"GenScript ProBio \/ DAAN Bio Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"GenScript ProBio \/ DAAN Bio Therapeutics"},{"orgOrder":0,"company":"GenScript ProBio","sponsor":"Selecxine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"SLC-3010","moa":"IL-2","graph1":"Oncology","graph2":"IND Enabling","graph3":"GenScript ProBio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"GenScript ProBio \/ GenScript ProBio","highestDevelopmentStatusID":"5","companyTruncated":"GenScript ProBio \/ GenScript ProBio"},{"orgOrder":0,"company":"GenScript ProBio","sponsor":"Bio Immunitas","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"","productType":"Large molecule","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"GenScript ProBio","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"GenScript ProBio \/ GenScript ProBio","highestDevelopmentStatusID":"3","companyTruncated":"GenScript ProBio \/ GenScript ProBio"},{"orgOrder":0,"company":"GenScript ProBio","sponsor":"RVAC Medicines","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2023","type":"Partnership","leadProduct":"RVM-V001","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"GenScript ProBio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"GenScript ProBio \/ RVAC Medicines","highestDevelopmentStatusID":"6","companyTruncated":"GenScript ProBio \/ RVAC Medicines"},{"orgOrder":0,"company":"GenScript ProBio","sponsor":"Eutilex Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"EU307","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"GenScript ProBio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"GenScript ProBio \/ GenScript ProBio","highestDevelopmentStatusID":"6","companyTruncated":"GenScript ProBio \/ GenScript ProBio"},{"orgOrder":0,"company":"GenScript ProBio","sponsor":"NuclixBio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Partnership","leadProduct":"Circular RNA-based Drug","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"GenScript ProBio","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"GenScript ProBio \/ GenScript ProBio","highestDevelopmentStatusID":"2","companyTruncated":"GenScript ProBio \/ GenScript ProBio"},{"orgOrder":0,"company":"GenScript Biotech Corporation","sponsor":"Legend Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"Ciltacabtagene Autoleucel","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"GenScript Biotech Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"GenScript Biotech Corporation \/ GenScript Biotech Corporation","highestDevelopmentStatusID":"14","companyTruncated":"GenScript Biotech Corporation \/ GenScript Biotech Corporation"}]

    Find Clinical Drug Pipeline Developments & Deals by GenScript Biotech Corporation

    Menu

    GenScript Biotech Corporation

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            GenScript Biotech Corporation

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            GenScript Biotech Corporation

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ciltacabtagene Autoleucel

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Recipient : Legend Biotech

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Legend Biotech's Cilta-cel Approved in China, Offering Hope for Multiple Myeloma Patients

                            Details : Carvykti (ciltacabtagene autoleucel) is a FDA approved BCMA-directed genetically modified autologous T cell immunotherapy indicated for the treatment of relapsed/refractory multiple myeloma in adults.

                            Brand Name : Carvykti

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            August 27, 2024

                            Lead Product(s) : Ciltacabtagene Autoleucel

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Recipient : Legend Biotech

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            GenScript ProBio

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            GenScript ProBio

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Circular RNA-based Drug

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Recipient : NuclixBio

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            GenScript ProBio Partners with NuclixBio to Pave the Way for South Korea’s First Large-scale Production Proc...

                            Details : Under the partnership, the compamies aims to develop the first circular RNA-based anticancer drug in South Korea using its next-generation mRNA therapy technology.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            November 09, 2023

                            Lead Product(s) : Circular RNA-based Drug

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Recipient : NuclixBio

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            GenScript ProBio

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            GenScript ProBio

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : EU307

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : Eutilex Inc

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            GenScript ProBio Congratulates Eutilex’s IND Clearance from MFDS

                            Details : EU307 is a fourth-generation CAR-T therapy which targets GPC3-positive solid cancer. It is expected to improve the viability of CAR-T cells and their ability to attack cancer cells through the secretion of cytokine (IL-18).

                            Brand Name : EU307

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            March 07, 2023

                            Lead Product(s) : EU307

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : Eutilex Inc

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            GenScript ProBio

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            GenScript ProBio

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RVM-V001

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : RVAC Medicines

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            GenScript ProBio and RVAC Medicines Announce Strategic Partnership for GMP Plasmid DNA Manufacturing for mRNA ...

                            Details : Under the agreement, GenScript ProBio will provide GMP plasmid manufacturing service for RVAC Medicines' program, RVM-V001. The partnership will accelerate its clinical manufacturing of future mRNA-based vaccines targeting infectious diseases such as RSV...

                            Brand Name : RVM-V001

                            Molecule Type : Vaccine

                            Upfront Cash : Undisclosed

                            February 22, 2023

                            Lead Product(s) : RVM-V001

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : RVAC Medicines

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            GenScript ProBio

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            GenScript ProBio

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Technology

                            Study Phase : Discovery Platform

                            Recipient : Bio Immunitas

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            A Joint Collaboration Between Bio Immunitas and GenScript ProBio Leads to the Development and Fast Track Manuf...

                            Details : GenScript ProBio provides IND-enabling CMC service for Bio Immunitas to accelerate the preclinical development of 2 recombinant protein products using Bio Immunitas' proprietary hRPP platform.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            February 08, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Technology

                            Highest Development Status : Discovery Platform

                            Recipient : Bio Immunitas

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            GenScript ProBio

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            GenScript ProBio

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SLC-3010

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Recipient : Selecxine

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            GenScript ProBio Congratulates Selecxine on FDA Clearance of IND Application for Innovative Antibody Drug Prog...

                            Details : SLC-3010 selectively stimulates anti-tumor immune response and the efficacy of SLC-3010 in eradication of various types of tumor was thoroughly demonstrated through various in vitro and in vivo experiments.

                            Brand Name : SLC-3010

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            August 23, 2022

                            Lead Product(s) : SLC-3010

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Recipient : Selecxine

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            GenScript ProBio

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            GenScript ProBio

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery Platform

                            Sponsor : DAAN Bio Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            GenScript ProBio and DAAN Bio Therapeutics, Sign a Strategic Cooperation MOU for the Discovery and Development...

                            Details : Through this agreement, both companies will strategically cooperate in the overall development process, such as discovery, manufacturing, and clinical trials of antibody and cell treatments, and related research and service projects.

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            July 14, 2022

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery Platform

                            Sponsor : DAAN Bio Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            GenScript ProBio

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            GenScript ProBio

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Genetically Modified Mesenchymal Stem Cells Therapy

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Recipient : AffyXell

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            AffyXell Expands its Strategic Partnership With GenScript ProBio

                            Details : The partnership covers process development and production of viral vectors required for the production of AffyXell’s future cell therapy products. The companies will collaborate in the area of business development, including potential out licensing.

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            May 16, 2022

                            Lead Product(s) : Genetically Modified Mesenchymal Stem Cells Therapy

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Recipient : AffyXell

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            GenScript ProBio

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            GenScript ProBio

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Single-domain Antibody

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Sponsor : AskGene Pharma Inc.

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            GenScript ProBio and AskGene Enter into a Non-exclusive License of A sdAb Targeting Immune Checkpoint Target

                            Details : The single-domain antibodies involved in this license agreement will be paired with AskGene's proprietary next-generation cytokine therapeutics for cancer immunotherapy and other applications.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            September 26, 2021

                            Lead Product(s) : Single-domain Antibody

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Sponsor : AskGene Pharma Inc.

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            GenScript ProBio

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            GenScript ProBio

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Flysyn

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Synimmune

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Gen Script Pro Bio Enters Into an Agreement with Synimmune for The Manufacture of Its Innovative Antibody Drug

                            Details : GenScript ProBio and SYNIMMUNE GmbH entered into collaboration on FLYSYN, a fms-like tyrosine kinase 3 (FLT3) specific antibody for the treatment of acute myeloid leukemia (AML) project for technology transfer and drug product for Clinical Phase II trial...

                            Brand Name : Flysyn

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            September 06, 2021

                            Lead Product(s) : Flysyn

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Synimmune

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth